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ABSTRACT
Introduction Delirium is a potentially preventable disorder
characterised by acute disturbances in attention and cognition
with fluctuating severity. Postoperative delirium is associated
with prolonged intensive care unit and hospital stay, cognitive
decline and mortality. The development of biomarkers for
tracking delirium could potentially aid in the early detection,
mitigation and assessment of response to interventions.
Because sleep disruption has been posited as a contributor
to the development of this syndrome, expression of abnormal
electroencephalography (EEG) patterns during sleep and
wakefulness may be informative. Here we hypothesise that
abnormal EEG patterns of sleep and wakefulness may serve as
predictive and diagnostic markers for postoperative delirium.
Such abnormal EEG patterns would mechanistically link
disrupted thalamocortical connectivity to this important clinical
syndrome.
Methods and analysis P-DROWS-E (Prognosticating
Delirium Recovery Outcomes Using Wakefulness and Sleep
Electroencephalography) is a 220-patient prospective
observational study. Patient eligibility criteria include
those who are English-speaking, age 60 years or older
and undergoing elective cardiac surgery requiring
cardiopulmonary bypass. EEG acquisition will occur 1–2
nights preoperatively, intraoperatively, and up to 7 days
postoperatively. Concurrent with EEG recordings, two times
per day postoperative Confusion Assessment Method
(CAM) evaluations will quantify the presence and severity
of delirium. EEG slow wave activity, sleep spindle density
and peak frequency of the posterior dominant rhythm will
be quantified. Linear mixed-effects models will be used
to evaluate the relationships between delirium severity/
duration and EEG measures as a function of time.
Ethics and dissemination P-DROWS-E is approved by
the ethics board at Washington University in St. Louis.
Recruitment began in October 2018. Dissemination plans

Strengths and limitations of this study
►► The

Prognosticating
Delirium
Recovery
Outcomes Using Wakefulness and Sleep
Electroencephalography study is a prospective observational study conducted in a perioperative patient population burdened with a high incidence of
postoperative delirium.
►► Longitudinal delirium assessments in tandem with
electroencephalography (EEG) across diverse states
of arousal will provide important insight into patient
trajectories throughout the perioperative period.
►► Coupling serial delirium assessments with structured chart review may improve sensitivity for detecting delirium despite its transient and fluctuating
nature.
►► Wireless wearable EEG recording devices outfitted
with dry electrodes allow for data acquisition with
minimal interference in patient care; however, sensitivity to motion artefact and patient tolerance may
challenge data acquisition and interpretation.
►► Prolonged postoperative sedation in the intensive
care unit may complicate the interpretation of delirium assessments and EEG.
include presentations at scientific conferences, scientific
publications and mass media.
Trial registration number NCT03291626.

INTRODUCTION
Postoperative delirium: a significant clinical
problem
Delirium is a potentially preventable disorder
with substantial negative impact on perioperative outcomes. Postoperative delirium
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Perioperative sleep disruption: a potential contributor to
delirium
Sleep addresses critical homoeostatic needs for restoring
physiological processes such that deficiencies result
in cognitive decrements and immune and endocrine
system impairments.23–25 Acute sleep deprivation is
linked to increases in oxidative stress, increased blood
brain barrier permeability and reduced clearance of

extracellular metabolites—all putative mechanisms
underlying postoperative delirium.26 Furthermore,
chronic sleep disorders are prevalent in neurodegenerative disorders including Alzheimer’s disease (AD) and
may increase delirium susceptibility.6 27 28 Advanced age
is also associated with sleep disorder prevalence,29 which
may increase delirium susceptibility in older adults. In
the perioperative arena, preliminary actigraphy studies
suggest an association between abnormal sleep–wake
cycle patterns and postoperative delirium.30–32 These
scale investistudies have not been followed by large-
gations of brain activity to examine the relationship
between sleep structure and delirium outcomes. This is
important because sleep may be a modifiable contributor to postoperative delirium.
Polysomnography (PSG), the gold-standard for studying
sleep, requires patients to be tethered to amplifiers and
acquisition computers. This hindrance to patient comfort
and postoperative rehabilitation has limited perioperative
studies of sleep. PSG relies on electroencephalographic
(EEG) waveforms to detect wakefulness and classify sleep
into distinct stages of rapid eye movement (REM) and
non-rapid eye movement (NREM) sleep.33 These stages,
interspersed in cycles throughout sleep, are defined by
well-known EEG waveforms and corresponding physiological processes (figure 1A). For instance, sleep spindles can
occur in stage N2 sleep, which comprises approximately
50% of total sleep time. The presence of EEG slow waves
defines stage N3 sleep, which is associated with restorative
physiological benefits across multiple organ systems.34–36
These EEG waveforms facilitate segmentation into sleep
stages and have characteristics in the frequency domain
(figure 1B).

Figure 1 Overnight electroencephalography (EEG). A hypnogram acquired with the EEG device reveals cycling of sleep stages
over an evening with wakefulness (W), rapid eye movement sleep (R) and non-rapid eye movement sleep stages (N1, N2 and
N3) (A). The corresponding spectrogram shows signal power in the frontal EEG decomposed by frequency as a function of
time. Slow waves (blue arrow) carry low frequency power during N3 sleep, while sleep spindles (red arrow) have power in higher
frequencies and occur primarily during N2 sleep (B). Sleep spindles (underlined) occurring at the point designated by the red
arrow in panel B are reflected by ~13 Hz power (C). Slow waves occurring at the point designated by the blue arrow in (B) are
reflected by 0.5–4 Hz power (D).
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is associated with prolonged hospitalisation, persistent
functional decline and mortality.1–6 Moreover, this postoperative problem is part of a larger problem that costs
the USA up to $152 billion annually.7 After major cardiac
and non-cardiac surgery, the incidence of delirium in
elderly patients is estimated to exceed 25%.8 9 However,
the condition may be underdiagnosed. First, assessment timing and frequency may compromise detection
because delirium exhibits a fluctuating course of inattention and disordered cognition. Manifestation peaks
within the first two postoperative days, but variance in
onset and recurrence impairs detection across individuals.10 11 Second, without use of sensitive screening
instruments, clinicians may underdiagnose the more
common hypoactive delirium subtype that arises subtly
as disorganised thinking and disengagement.11–15 Finally,
subsyndromal delirium may also be difficult to detect as
patients may show signs without fulfilling all diagnostic
criteria.16–18 These cases are clinically impactful and have
been targeted for palliative intervention due to associated poor outcomes.17–22 Despite this, no quantitative
biomarkers exist that predict delirium onset, trajectory
or severity. Identifying such prognostic markers may help
develop preventative or abortive therapies and may elucidate underlying neural mechanisms.

Open access

EEG markers of sleep and wakefulness and thalamocortical
disruption
Sleep stages, characterised by EEG waveform morphology,
are normally regulated by circadian and sleep homoeostatic processes.47 48 Preliminary studies in critically ill,
ventilated patients with delirium have revealed abnormal
EEG waveform characteristics corresponding to sleep–
wake states. For instance, sleep spindles are absent during
phenotypic sleep while slow waves are present during
apparent wakefulness.49 50 Taken together, these data
suggest that investigating EEG during perioperative sleep
and wakefulness may aid in correlative studies on the time
course of delirium onset.
Sleep spindles
Originally described by Loomis et al,51 EEG sleep spindles
reflect thalamocortical connectivity for sustaining sleep
and consolidating memory.52 These oscillations in N2
and N3 sleep (reviewed in Loomis et al53) originate from
the thalamic reticular nucleus and propagate across the
cortex with differential expression patterns in occipital
and frontal EEG.54 55 Sleep spindles possess a waxing and
waning pattern of at least 0.5 s in duration (figure 1C).
Within an individual, the dominant frequency of sleep
spindles in the 9–16 Hz range is conserved.56 Sleep
spindle expression is under inverse homoeostatic
control with a reduction in density following acute sleep
deprivation.57 Sleep spindle density, calculated as the
number of spindles per unit time, varies over an evening
of sleep.58 59 This measure may be a useful marker of
chronic sleep deprivation and cognitive dysfunction;
decrements mirror the severity of cognitive episodic
memory dysfunction in AD patients.58 60 Furthermore,
abnormal sleep spindle expression occurs in patients
with severe dementia and schizophrenia and is predictive
of dementia in patients with Parkinson’s disease years
after measurement.61–64 Analogues of sleep spindles are
observed during sedation and general anaesthesia with
an unknown impact on subsequent homoeostatic regulation and expression.65–67 Overall, perioperative sleep
spindle expression has not been characterised or related
to perioperative outcomes.
Smith SK, et al. BMJ Open 2020;10:e044295. doi:10.1136/bmjopen-2020-044295

Slow wave activity
Sleep slow waves are characteristic of N3 sleep and may
be useful for tracking cognitive function.68 They are
putative markers of synaptic pruning, memory consolidation and have been related to the clearance of beta-
amyloid and other metabolites.69–72 Sleep slow waves are
defined through high amplitude, low frequency oscillations on EEG (figure 1D). In order to correlate cognitive
function with low frequency oscillation amplitude, sleep
slow wave activity (SWA) is calculated as the total EEG
power of contributory low frequencies (eg, 1–4 Hz) per
minute.73 74 Regional sleep SWA positively correlates with
learning and subsequent visuomotor task performance75
that may be impaired by auditory interventions.76 Exogenous enhancement of SWA potentiates memory and
task performance.77 In contrast, selective acute SWA
deprivation induces a rebound in magnitude on the next
day based on the preceding deficit.78–80 Furthermore,
reduced SWA is associated with beta amyloid deposition,
tau pathology,81 atrophy in prefrontal cortical regions
and impaired memory.71 82
In adults, slow waves observed during wakefulness83–86
are usually associated with underlying structural or
functional pathology.87 Moreover, diffuse slow waves
may represent disrupted thalamocortical connectivity.88
Previous work has identified slow waves during apparent
wakefulness in patients with postoperative delirium.89–91
Furthermore, low EEG frequency predominance has been
reported as a non-specific marker of hepatic encephalopathy,92–95 sepsis-associated encephalopathy96–99 and postoperative delirium.89 90 100–109 Slow waves are associated
with altered thalamocortical connectivity during general
anaesthesia.110 Whether overexpression of slow waves
during wakefulness precedes postoperative delirium
remains unknown.
Posterior dominant rhythm
The posterior dominant rhythm (PDR) is a robust
marker of thalamocortical connectivity, integrity and
cognitive function during relaxed wakefulness with eyes
closed.33 111 112 The PDR consists of oscillations evoked by
eyelid closure that have greatest amplitude in occipital
EEG derivations.112 113 For the vast majority of adults, the
dominant frequency of the PDR lies within the 8–13 Hz
(alpha) frequency band (figure 2). Lower PDR frequencies observed in AD patients are associated with thalamic
deficiencies of norepinephrine.114 115 Similarly, low PDR
frequencies during apparent wakefulness have shown
promise as a marker of early and advanced cognitive
impairment of AD.116–120 The severity of slowing appears
to correlate with the degree of cognitive impairment121–125
but has not been evaluated longitudinally in the perioperative period.
Hypotheses and aims
We hypothesise that delirium is a disorder of both sleep
and wakefulness resulting from abnormal thalamocortical connectivity. Furthermore, we hypothesise that
3
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Despite technical limitations, small studies have
demonstrated profound postoperative changes in sleep
architecture with unknown clinical implications. N3
sleep suppression occurs on the day of anaesthesia in
volunteer studies and persists on subsequent postoperative nights.37 38 Fragmentation of sleep architecture and
overexpression of N2 with reduction of N3 and REM
sleep occur in the first postoperative night following both
cardiac and non-cardiac surgery.38–45 N3 and REM sleep
return on the third or fourth postoperative nights.32 38 43 46
However, the clinical impact of NREM sleep disruption
remains unclear as EEG waveforms defining different
sleep stages have not been related to postoperative
delirium or other perioperative outcomes.

Open access

EEG alterations can predict delirium onset and severity.
Our specific aims include the following: (1) evaluate
whether preoperative EEG measures of sleep and wakefulness predict postoperative delirium and its severity;
and (2) assess whether postoperative abnormalities in
EEG measures of sleep and wakefulness correlate with
delirium onset, severity and clinical course. For our
first aim, we hypothesise that the EEG power of preoperative sleep slow waves, sleep spindle density and PDR
frequency will correlate negatively with the peak severity
of postoperative delirium. Our second aim, focused on
postoperative findings, addresses three hypotheses: (1)
delirium onset and peak severity will correlate with an
increase in SWA and diminished PDR frequency during
wakefulness; (2) delirium onset and peak severity will
correlate with the reduction in postoperative sleep
spindle density relative to preoperative measurements;
4

(3) delirium recovery will coincide with a reversion of
the dominant PDR frequencies toward preoperative
values.

METHODS
Research design overview
Prognosticating Delirium Recovery Outcomes Using
Wakefulness
and
Sleep
Electroencephalography
(P-DROWS-E) is a prospective longitudinal cohort observational investigation. The Human Research Protection
Office at Washington University School of Medicine
approved the study in 2017. P-
DROWS-
E was registered prior to enrolment and conforms to the Standard
Protocol Items: Recommendations for Interventional
Trials checklist (see online supplemental file 1).
Smith SK, et al. BMJ Open 2020;10:e044295. doi:10.1136/bmjopen-2020-044295
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Figure 2 The posterior dominant rhythm (PDR) during eyes closed wakefulness using the electroencephalography (EEG)
recording device. Alpha oscillations are not easily discernable during eyes open wakefulness (A). During eyes closed
wakefulness, the PDR in cognitively intact adults is comprised oscillations in the alpha (8–13 Hz) frequency band (B). This
activity is apparent in the decomposition of these two signals into power at corresponding frequencies by spectral analysis. The
PDR emerges during eyes closed wakefulness with signal power at ~10 Hz (blue) compared with signal power during eyes open
(red) (C). A power spectrogram demonstrates quantifiable fluctuations in the ~10 Hz power during epochs of eyes open vs eyes
closed wakefulness (red vs blue arrow) (D).

Open access

Recruitment
Recruitment and enrolment of eligible patients will occur
following screening of the cardiac surgery schedule at
Barnes-
Jewish Hospital, the Center for Preoperative
Assessment and Planning clinic schedule, and inpatient
census lists from cardiology and cardiothoracic wards by
study coordinators.
Data collection
Preoperative screening and assessment tools
Baseline sleep–wake function will be evaluated through
questionnaires including daytime sleepiness with the
Epworth Sleepiness Scale,126 overall sleep–wake function
with the Patient Reported Outcomes Measurement Information System (PROMIS) Sleep Related Impairment/
Sleep Disturbance Scale,127 sleep quality with the Pittsburgh Sleep Quality Index128 and obstructive sleep apnoea
risk estimation with the Snoring, Tiredness, Observed
apnea, high blood-Pressure, BMI, Age, Neck circumference, and male Gender (STOP-BANG) questionnaire.129
Baseline depression, cognition and prior education are
prognostic factors for postoperative delirium. Therefore,
patients will complete the Geriatric Depression Scale
short form130 and the Montreal Cognitive Assessment,
which screen for cognitive impairment.131 In addition,
the AD-8,132 a rapid screen that has been validated against
AD biomarkers, will be used.133 The number of years of
education will also be recorded. Finally, the CAM134 and
serial pain assessments will be performed.
Confusion assessment method
The CAM is used to diagnose delirium based on five key
domains: (1) acute onset, (2) fluctuating course, (3) inattention, (4) disorganised thinking and (5) altered level
of consciousness.134 It is a validated tool for delirium
diagnosis with a sensitivity of 94% and specificity of
89% against full neuropsychiatric evaluation.135 CAM
Smith SK, et al. BMJ Open 2020;10:e044295. doi:10.1136/bmjopen-2020-044295

administration takes 10–20 min at our institution and
consists of a formal patient interview comprised questions
that identify delirium symptoms and test cognition.
CAM assessments will be performed by researchers
who have undergone an established rigorous training
process.136 137 All assessments will be independently
reviewed by a separate, trained research team member for
internal scoring consistency and completeness. Ambiguous assessments will be reviewed by the research team
and PI weekly with concomitant adjudication of each
domain and the overall delirium determination. The
patient’s family and nurse are also questioned about the
patient’s postoperative mental status as needed. Patients
whose medical condition prohibits the use of the CAM
will be assessed using the CAM for the intensive care unit
(CAM-ICU) instrument.138 139 Both the CAM-ICU and the
CAM have been shown have good agreement with the
Diagnostic and Statistical Manual of Mental Disorders
(DSM)-IV criteria for delirium.140–142
Pain assessments
A limited number of studies suggest an association
between acute postoperative pain and delirium.143–145
Therefore, serial pain evaluations will be completed using
the Behavioral Pain Scale (BPS)/BPS Non-Intubated and
the Visual Analog Scale.146 Evaluations will be performed
after each CAM assessment.
EEG apparatus
Perioperative EEG will be used to assess markers of wakefulness, sleep and delirium. To address the technical
limitations of PSG, we will employ a consumer-
grade
wearable wireless EEG device (Dreem, Rhythm, New York,
New York, USA) requiring minimal clinical intervention
and maintenance (figure 3A).147 148 It yields continuous
multichannel EEG data through dry electrodes, heart rate
through infrared detectors and head movement through
accelerometers. In addition to frontal forehead sensors
(F7, F8 and Fpz), occipital EEG signals are acquired using
posterior sensors (O1 and O2). Adequate signal quality
will be assessed by research staff.
Preoperative EEG acquisition
To maximise patient compliance and signal quality,
research staff will demonstrate wireless EEG device usage.
Patient head circumference will be measured, and the
device will be adjusted for proper fit. To obtain baseline
PDR, patients will be asked to remain still and relaxed for
4 min with eyes open followed by a 4 min period of eyes
closed (figure 3B). Patients will demonstrate comprehension by donning the device and initiating a recording
themselves.
Patients will be requested to wear the device for up to
two nights before surgery to allow for EEG sleep structure
assessment. For inpatients, research staff may assist with
device application. For outpatients, the device, charger,
alcohol wipes, an educational video and an instruction
sheet will be provided. Research staff will also be available
5
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Study participants
We will enrol 220 patients undergoing elective cardiac
surgery at Barnes-
Jewish Hospital, St. Louis, Missouri.
Inclusion criteria are (1) English-speaking, (2) age 60
years or older and (3) undergoing elective major cardiac
surgery requiring cardiopulmonary bypass (eg, coronary
artery bypass grafting, aortic repair/replacement, septal
myectomy, Maze procedure and/or heart valve repair/
replacement). Exclusion criteria are (1) undergoing
surgery requiring deep hypothermic circulatory arrest,
(2) pre-existing delirium, defined by a positive preoperative confusion assessment method (CAM) evaluation
and (3) inability to participate sufficiently in delirium
screening due to deafness, blindness or poor English
fluency. We minimised exclusion criteria to maximise
generalisability of findings to the general cardiac surgical
population. Participants will be compensated for their
efforts: $50 for each preoperative EEG recording and $25
for each intraoperative and postoperative EEG recording,
up to $300.

Open access

by phone to address questions. Patients will be contacted
by phone to ensure compliance, satisfaction and data
quality.
Day of surgery EEG acquisition
If necessary, additional preoperative awake EEG data will
be obtained. The Dreem will then be used throughout
anaesthetic induction, maintenance and emergence
(figure 3B). Research staff will optimise EEG acquisition
through device adjustments, as needed.
Postoperative EEG acquisition, delirium assessments and pain
scores
Semi-
continuous EEG recordings will be acquired up
to postoperative day (POD) 7, patient withdrawal or
hospital discharge (figure 3B). To enhance data collection, participants will be asked to wear the device within
2 hours of 07:00, 13:00 and 19:00 for 4 min each during
eyes open and eyes closed periods. The 07:00 and 19:00
recording sessions will coincide with acquisition of CAM
and pain scores. CAM-ICU will be used for intubated
patients.149 EEG but not CAM data will be obtained for
unresponsive patients (Richmond Agitation-
Sedation
Scale (RASS)150 level −4 or −5). Participants will wear
the device overnight to provide data on nocturnal sleep
structure.
6

Structured chart review for delirium
Coupling structured chart review with CAM/CAM-ICU
increases sensitivity in detection of delirium without loss
of specificity.151 152 Therefore, formal structured chart
reviews will be performed by independent trained clinical researchers who are blinded to EEG and CAM data.
Reviews will occur daily until POD 7. The chart review
methodology (table 1) will use patient information
from the electronic medical record including mental
status, progress notes, medication usage (including
psychotropic, sedative and pain medications) and relevant clinical details (eg, length of stay, ICU behavioural
interventions, extubation and/or re-
intubation procedures, etc).151 152 Structured chart review training will be
adapted from previously published methods,152 and only
CAM trained staff will be eligible. In cases where chart
review delirium outcome is uncertain, a consensus review
will occur. In cases where chart review is discordant with
both CAM assessments on a given day, a formally trained
attending clinician blinded to all other metrics will determine the final outcome.
Analyses
EEG preprocessing and analysis
EEGLAB,153 an open-source analytical suite for MATLAB
(Mathworks, Natick, Massachusetts, USA), will be used
Smith SK, et al. BMJ Open 2020;10:e044295. doi:10.1136/bmjopen-2020-044295
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Figure 3 Overview of electroencephalography (EEG) device and patient participation workflow. Perioperative EEG will
be obtained via the Dreem device, a consumer-grade wireless wearable EEG device that records from five sensors, pulse
oximetry and accelerometry (A). Longitudinal assessments of EEG and delirium symptomatology will occur preoperatively,
intraoperatively and postoperatively. Following consent in the Center for Preoperative Assessment and Planning/inpatient unit,
a baseline confusion assessment method (CAM) and EEG are acquired. Postoperative daytime assessments occur within a
2-hour window surrounding 07:00, 13:00 and 19:00 until postoperative day 7, patient withdrawal or hospital discharge (B). The
human in this figure is a model and not a patient. Permission was granted for non-commercial use of this image by Dreem.
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Was delirium diagnosed by a clinical provider?
(Review diagnosis code summary in electronic medical record for any diagnoses related to delirium.)

►► Yes
►► No
►► Uncertain

Was there any evidence in the chart of acute confusion (eg, delirium, mental status change,
disorientation, hallucinations, agitation, etc)?
(Review all handwritten and electronic notes, flowsheet data, and documented CAM-ICU results
performed twice daily by nursing staff.)

►► Yes
►► No
►► Uncertain

Was there any documentation of the use of delirium prevention strategies at any time during the
hospitalisation before delirium occurred?
(Review flowsheet data for nursing interventions such as reorienting patient to room, equipment,
unfamiliar surroundings, person, situation, time and adjustment of lighting during day.)

►► Yes
►► No
►► Uncertain

Was there any documentation of the use of a restraint or bed alarm/device recorded during the
patient’s stay?
(Review flowsheet data for documentation of any restraint devices used.)

►► Yes
►► No
►► Uncertain

Outcome
By chart review, delirium was

►► Present
►► Absent
►► Uncertain
►► Cannot be

determined

Outcome is determined after a complete review of the medical record. Questions 1–4 are designed to help the reviewer identify evidence of
delirium consistent with diagnostic criteria including an acute change or fluctuating course, inattention and disorganised thinking or altered
level of consciousness.
CAM-ICU, confusion assessment method for the intensive care unit.

for down-
sampling deidentfied EEG to 128 Hz after
band-pass filtering (0.1–50 Hz first order Butterworth).
Records will undergo visualisation and artefact removal
using EEGLAB plugins and/or custom-coded MATLAB
scripts. Multitaper methods will be used for power spectral analysis using the MATLAB Chronux toolbox.154
Spectral estimates between 0.5 and 30 Hz will be based
on 6 s non-overlapping time windows, time-bandwidth
product of 3 and 5 tapers.
Sleep technologist scoring
Records will undergo sleep staging with visualisation in
Philips Respironics Sleepware G3 Software. They will be
scored successively with a low frequency filter (LFF) of
1 Hz then 0.3 Hz and a high frequency filter of 30 Hz.
The LFF of 1 Hz will attenuate artefacts related to sweat,
respiration and movement. Rescoring with an LFF of 0.3
Hz will allow for best quantification of SWA and stage N3
sleep. Channels Fpz-F8, Fpz-F7 and F8-F7 will be used
for visual scoring, while occipital derivations will be used
secondarily. Additionally, accelerometer channels will
be used to identify movement, respiratory patterns and
arousals. Registered polysomnographic technologists
will score the record in 30 s epochs using the modified
American Association of Sleep Medicine (AASM) criteria
(table 2).33 Evaluators will be blinded to delirium clinical outcomes and automated scoring provided by the
manufacturer.
Quantitative measures of sleep spindle and slow waves
Sleep spindles will be scored manually by registered polysomnographic technologists using AASM guidelines and
Smith SK, et al. BMJ Open 2020;10:e044295. doi:10.1136/bmjopen-2020-044295

with the assistance of publicly available algorithms implemented in our laboratory.63 155–162 Spindle density will be
computed from the number of spindles per minute of N2
and N3 sleep. Dissipation in sleep spindle power (ie, total
power across 11–16 Hz) will be assessed over the course
of nocturnal sleep.
Custom-written MATLAB subroutines will compute the
SWA as the total absolute spectral power in the 1–4 Hz
frequency band, calculated in 1 min intervals during N2
and N3 sleep.163 Custom-written MATLAB code will be
used to detect individual slow waves and calculate their
power.164 For our second aim, predictor SWA measurements during phenotypic wakefulness will be computed
from postoperative recordings where EEG slowing is
noted despite persistent criteria for wakefulness (eg, eye
movements, high frequency activity (>30 Hz) and motion
artefact). Registered sleep technologists will review these
expected discordant epochs.
Quantitative measures of the PDR
Previously developed MATLAB scripts will be used to
quantify PDR frequency from EEG recorded during eye
closure. Registered sleep technologists will first screen
the occipital EEG (Fpz-O1, Fpz-O2, O1-O2) recorded
during eyes closed wakefulness (07:00, 13:00 and 19:00)
to identify recording contamination by sleep. Band-pass
filtering of the signals will then occur, and spectral estimates will be generated through the Chronux toolbox
modules.154 PDR frequency will be determined based on
peak power.
7

BMJ Open: first published as 10.1136/bmjopen-2020-044295 on 13 December 2020. Downloaded from http://bmjopen.bmj.com/ on August 10, 2021 by guest. Protected by copyright.

Table 1 Chart abstraction for delirium during hospitalisation
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Stage

Criteria/description

W

>50% epoch contains any of the following
Posterior dominant rhythm: 8–13 Hz EEG oscillations over occipital region with eyes closed
Eye blinks: vertical eye movements of 0.5–2 Hz
Slow eye movements: conjugate, sinusoidal eye movements
Rapid eye movements: conjugate, irregular, sharply peaked eye movements
Posterior dominant rhythm absent with any of the following
Low amplitude mixed frequency EEG: 4–7 Hz activity
Vertex sharp waves: EEG sharp waves with duration <0.5 s
Slow eye movements: conjugate, sinusoidal or slow eye movements

N1

N2

Either present during the first half of an epoch or last half of previous epoch
K-complexes: EEG negative sharp wave and positive component with total duration >0.5 s and without arousal
Sleep spindles: crescendo-decrescendo EEG oscillatory pattern with frequency 11–16 Hz and duration of 0.5–3 s

N3

Presence over >20% of an epoch
EEG slow waves: delta waves with a frequency 0.5–4 Hz and peak-to-peak amplitude >60 μV

R

All of the following present
Low amplitude mixed frequency EEG: 4–7 Hz EEG activity without K-complexes or sleep spindles
Sawtooth waves: EEG train of sharply contoured or triangular waves with frequency of 2–6 Hz
Rapid eye movements: conjugate, irregular, sharply peaked eye movements
Epoch cannot be scored due to excessive artefact and/or inability to fulfil criteria for above stages

NS

EEG, electroencephalography.

Processing of delirium outcomes
Daily delirium incidence will be coded as a binary variable defined by a positive CAM assessment and/or chart
review. Delirium duration will be coded as a categorical
variable defined by the total number of days with a positive delirium outcome, ranging from 0 to 7. Delirium
subtype (hypoactive, hyperactive or mixed), based on the
RASS and the CAM, will also be noted. Delirium severity
will be quantified using the CAM-S and/or CAM-ICU 7.
The CAM-S is a validated weighting of CAM sub-scores,165
with a long-
form version ranging from 0 to 19. The
CAM-ICU-7166 is a validated weighting of the CAM-ICU
subscore ranging from 0 to 7. Raw severity scores will be
normalised by the maximum score of the tool in order
to yield scaled severity scores ranging from 0 to 1. The
maximum scaled delirium severity score will be coded as
a continuous variable in analytical models.
Statistical analyses
Linear mixed effects models will be used to evaluate
relationships between EEG measures and delirium
severity and duration. For our first aim, principal independent variables will include preoperative measures of
sleep spindle density, sleep SWA for stages N2 and N3,
and PDR frequency. For our second aim, independent
variables will include EEG changes relative to preoperative baseline for sleep spindle density, awake SWA and
PDR frequency. Given that EEG measures may vary by
age167–169 and sex,163 170 these factors will be included
as relevant biological variables. Secondary analytical
models will include relevant medications and comorbidities such as obstructive sleep apnea and depression
as well as years of education. Additional covariates to
8

account for intraoperative anaesthetic exposure will use
intraoperative measures of SWA, sleep spindle density
and burst suppression171–173 derived from intraoperative
EEG device recordings. As we expect that only 25% of
our patients may develop postoperative delirium, we will
consider zero-inflated models.
Sample size calculations
Considering the heterogeneity of delirium phenotype
and variable exposure to narcotics and other medications, we expect a large sample size to reduce the risk of
completing an underpowered study. Based on preoperative recruitment of 220 patients, we expect 95% capture
rate for preoperative and intraoperative recordings, and
a 25% incidence of delirium based on results from the
Electroencephalography Guidance of Anesthesia to Alleviate Geriatric Syndromes (ENGAGES) study,173 with the
majority completing delirium assessments throughout
the postoperative period. We expect at least 70% of
these patients to provide usable postoperative EEG. We
anticipate the ability to capture at least moderate effects
(effect size 0.5, beta 0.2, power 0.8) based on conventions for statistical power analysis in the behavioural
sciences.174
Prespecified substudies
Other physiological markers for predicting delirium outcomes
Additional physiological markers (accelerometry, blinks
and heart rate measurements), and sleep EEG markers,
including N1 vertex waves, N2 K-complexes and REM
sawtooth waves will be evaluated against delirium
outcomes.
Smith SK, et al. BMJ Open 2020;10:e044295. doi:10.1136/bmjopen-2020-044295
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Table 2 Modified American Association of Sleep Medicine scoring criteria for different sleep stages
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Postoperative cognitive trajectories
This substudy uses a modified version of the Brief Test
of Adult Cognition by Telephone to determine the rate
of postoperative cognitive recovery and how delirium
impacts cognitive recovery via interval assessments up
to 6 months after surgery.175 176 The battery will evaluate
multiple cognitive domains including episodic memory,
working memory, processing speed, attention and executive function. Associations between EEG measures and
cognitive function will also be evaluated.
Automated sleep staging
Staging provided by the manufacturer’s automated algorithm will be compared with the manual sleep staging
performed by registered PSG technologists.
Relationship of sleep structure to clinical outcomes
Preoperative EEG/sleep measures, sleep surveys (Epworth
Sleepiness Scale, STOP BANG) and Geriatric Depression
Scale scores will be evaluated against secondary postoperative clinical outcomes, including 30-day mortality, ICU
length of stay, depression, atrial fibrillation and acute and
persistent pain scores.

Comparisons of sleep and sleep-like EEG markers
Within-subject comparisons will be made between EEG
markers spanning different states of arousal.
Utility of intraoperative EEG markers
Intraoperative EEG measures, including burst suppression will be evaluated against postoperative outcomes.
DISCUSSION
The P-
DROWS-
E study aims to enhance our understanding of perioperative delirium. We will use EEG
recordings acquired across different states of arousal in
tandem with serial perioperative delirium assessments to
determine temporal associations between EEG markers
and postoperative delirium outcomes. Our work is
enhanced by integrating additional data including assessments of cognition and clinical variables (figure 4). As a
result, we are well positioned to develop analytical models
for predictive and diagnostic EEG markers of postoperative delirium.
Until recently, technical limitations have impeded
incisive probing of the relationships between sleep
architecture and postoperative delirium. Our study uses
a battery-
operated, portable device that is specifically
designed for continuous long-
term EEG recordings
with minimal need for direct assistance by staff. This
approach should greatly enhance patient participation,
tolerance and comfort while posing minimal interference to postoperative sleep and rehabilitation. The EEG

Figure 4 Prognosticating Delirium Recovery Outcomes Using Wakefulness and Sleep Electroencephalography study overview.
CAM, confusion assessment method; EEG, electroencephalography; PDR, posterior dominant rhythm; SWA, slow wave activity.
Smith SK, et al. BMJ Open 2020;10:e044295. doi:10.1136/bmjopen-2020-044295
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Device validation for elderly patients
This substudy will compare Dreem data and PSG in the
geriatric population to complement early studies across
a broad age.148
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INFORMED CONSENT DOCUMENT
Project Title: P-DROWS-E / Prognosticating Delirium Recovery Outcomes Using Wakefulness
and Sleep Electroencephalography
Principal Investigator:

Ben J.A. Palanca, MD, PhD, MSc

Research Team Contact:

Thomas Nguyen, Nguyen.t@wustl.edu, 314-273-2454

This consent form describes the research study and helps you decide if you want to participate. It
provides important information about what you will be asked to do during the study, about the risks and
benefits of the study, and about your rights and responsibilities as a research participant. By signing this
form, you are agreeing to participate in this study.
• You should read and understand the information in this document including the procedures,
risks and potential benefits.
• If you have questions about anything in this form, you should ask the research team for more
information before you agree to participate.
• You may also wish to talk to your family or friends about your participation in this study.
• Do not agree to participate in this study unless the research team has answered your
questions and you decide that you want to be part of this study.
WHAT IS THE PURPOSE OF THIS STUDY?
This is a research study. We invite you to participate in this research study because you are going to
undergo a cardiac surgical procedure. We want to understand your sleep and brain function before,
during, and after surgery.
Postoperative delirium is a condition in which patients develop temporary difficulties in maintaining
attention and thinking clearly. These new problems can appear after surgery and change throughout the
day. This confusion can last several days.
The overall purpose of this study is to measure brain activity during sleep and wakefulness to learn
about their relationships to delirium after surgery. While you may not feel like your normal self during
the study, you are in the best position to help us learn how to improve the recovery of brain function and
sleep in others having surgery. We need to learn from those who have and have not become confused
after their surgical procedure.
WHAT WILL HAPPEN DURING THIS STUDY?
Your participation in this study involves the study of your brain activity at three periods: (1) 1-2 days
within the weeks before you undergo surgery, (2) during surgery, and (3) for up to 7 days after you have
had surgery. We may also contact you after hospital discharge to study your thinking abilities. This
research study will take place at home and at the Washington University School of Medicine campus.
Recording Before Surgery: The research team will show you how to wear a lightweight headband for the
study. This device, the DREEM is used to assess sleep quality at home. It will allow us to record brain
electrical activity from your scalp, using electroencephalography, or EEG. EEG is currently used to
study brain function in the operating room and for assisting in the diagnosis of sleep problems.
6/15/2020
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First, we will show you the DREEM, and how to wear it. After we show you an instruction card, we will
determine the best fit for wearing the device. We will then have you wear the DREEM so that we may
obtain baseline data. We will then ask you to stay awake with your eyes closed and open. We may ask
you to do some simple tasks, such as wiggling your toes or tapping your fingers. The research team will
also ask you some questions about any pain you are experiencing and how you are thinking and feeling.
You will also be asked to complete a short cognitive assessment and fill out surveys regarding your
quality of sleep and sleep habits, how sleepy you feel during various activities, your mood, and some
basic demographic information. We will then send you home with the DREEM to wear while you sleep
for 1-2 nights before you have surgery. We will call you before and after every day of recording to assist
you in this process.
We will ask you to bring the DREEM back on the day of surgery. Alternatively, if you are in the
hospital on the night before surgery, we will help you wear it and discuss with your nurses and doctors
how it will not impede their care for you.
Alternate Operations Due to COVID-19: The research team will send a lightweight headband to your
home. We will email or text you a link to an instructional video to show you how to use the device and a
link to complete our surveys electronically. Before going to sleep, you will be asked to stay awake with
your eyes open for 4 minutes followed by eyes closed for 4 minutes while wearing the headband. We
will contact you before and after each day of recording to assist you in this process. Depending on your
convenience, we will ask you to bring the DREEM back on the day of surgery or ship the device back to
us using a prepaid shipping package.
Recording During Surgery: Before you go into surgery, a member of the research team will help you
wear the DREEM. We may ask you to remain awake with your eyes open and closed for a few minutes
before you wear it throughout your surgery. We will be in contact with your nurses and physicians to
ensure that the device will not interfere with your care.
Alternate Operations Due to COVID-19: On the day of surgery, we may also you to complete a short
cognitive assessment before surgery due to limited in-person interaction at baseline.
Recording After Surgery: After your surgery is completed, the research team will check on the device
and have you continue wearing the DREEM throughout the day and night. This will continue up to the
first seven days after surgery. The team will ask you more questions about any pain you are
experiencing and how you are thinking and feeling. We will again ask you to do simple tasks or to
otherwise lay still with your eyes closed. Our interaction with you on these days will mainly be around 7
AM, 1 PM, and 7 PM, and should take roughly 10-30 minutes. At this time, we can also adjust the
device to improve your comfort if needed.
Outpatient Follow-Up: After you have left the hospital, we may contact you at certain time points to
assess your thinking. This will be performed by phone or in the hospital. We would do our best to
coordinate with your clinical follow-up appointments. During these 15-20 minute follow-ups, we will
ask you to answer a series of questions. We will audio-record these interactions to better interpret your
responses. If the follow-up is in person, you may be asked to wear the DREEM device during the
session.
At the above time points and after the study, we will want to check on your satisfaction and determine
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ways to improve comfort and tolerability, to aid future patients in the study. Additionally, we may
continually monitor your electronic medical record during your enrollment to help coordinate timing of
study procedures. We will also collect information from your electronic medical record pertaining to
your surgery, recovery progress, and indicators of mental status including delirium. We would continue
accessing these data after you have been discharged from the hospital.
Will you save my samples or research data to use in future research studies?
As part of this study, we are obtaining cognitive assessments and EEG data from you. We would like to
use these data for studies going on right now as well as studies that are conducted in the future. These
studies may provide additional information that will be helpful in understanding brain recovery after
surgery or other diseases or conditions, including research to develop investigational tests, treatments,
drugs or devices that are not yet approved by the U.S. Food and Drug Administration. It is unlikely that
what we learn from these studies will have a direct benefit to you. There are no plans to provide
financial compensation to you should this occur. By allowing us to use your EEG data, you give up any
property rights you may have in the EEG data.
We will share your data with other researchers. These researchers may be at Washington University, at
other research centers and institutions, or industry sponsors of research. We may also share your
research data with large data repositories (a repository is a database of information) for broad sharing
with the research community. If your individual research data is placed in one of these repositories only
qualified researchers, who have received prior approval from individuals that monitor the use of the
data, will be able to look at your information.
Your data will be stored without your name or any other kind of link that would enable us to identify
which sample(s) or data are yours. Therefore, it will be available for use in future research studies
indefinitely and cannot be removed.
Video Recording/Photographs/Audio Recording
Part of the study involves videotaping and/or photographing the DREEM headband while it is on your
head. Video clips and/or photographs of our recording sessions will be used to gauge your brain state,
allow for prompt intervention in the case of any safety concerns, and for demonstration purposes for
potential participants.
We will also use the photographs and/or video clippings in future abstract/manuscript submissions or
academic conferences. It is customary to include photographs or video clips when presenting findings
using new brain monitoring technologies. No identifiers or personal health information will be
associated with the photographic or video materials used in publications, beyond the images. Reasonable
efforts will be made to conceal your identity if the pictures or images are used. Your eyes will be
covered in photographs to hide your identity.
Video will be stored electronically with an assigned code instead of your name and will be accessible
only to the research staff on this project. Videos and photos used for education will be kept for 7 years.
For academic presentations, we will keep the videos/photos indefinitely. Alternatively, they may be
destroyed upon the participant’s written request.
Additionally, audio recordings may be requested for the cognitive task performance portion of the study.
These recordings will only contain responses to task items and no identifying information aside from
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coded subject identifiers. These recordings will be used to further evaluate and verify your cognitive
performance during certain tasks.
I give you permission to make video recordings/photographs/audio recordings of me during this study.
_____ Yes
Initials

_____ No
Initials

HOW MANY PEOPLE WILL PARTICIPATE?
Approximately 220 people will take part in this study conducted by investigators at Washington
University.
HOW LONG WILL I BE IN THIS STUDY?
Your direct participation in the study will take up to 10 days, with one – two days of recording before
surgery and seven days of recording during and after surgery. We will contact you within a week after
your enrollment in the study in person or by telephone to obtain feedback from your experience in the
study. We would like to determine whether you had any problems during your involvement. We will
also maintain phone contact in the months after your inpatient stay to coordinate and collect data on
your thinking abilities.
WHAT ARE THE RISKS OF THIS STUDY?
You may experience one or more of the risks indicated below from being in this study. In addition to
these, there may be other unknown risks, or risks that we did not anticipate, associated with being in this
study.
DREEM EEG [Electroencephalography]: Skin irritation may occur from wearing these electrodes.
Some discomfort may occur when we change the electrodes, particularly those over your hair.
Questionnaires: There are no risks associated with the questionnaires.
Breach of Confidentiality: One risk of participating in this study is that confidential information about
you may be accidentally disclosed. We will use our best efforts to keep the information about you
secure. Please see the section in this consent form titled “How will you keep my information
confidential?” for more information.
WHAT ARE THE BENEFITS OF THIS STUDY?
You will not benefit from being in this study. However, we hope that, in the future, other people might
benefit from this study because the results may increase our understanding of the changes in brain
function after surgery.
WILL IT COST ME ANYTHING TO BE IN THIS STUDY?
You will not have any costs for being in this research study.
You and/or your medical/hospital insurance provider will remain responsible for your regular medical
care expenses.
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WILL I BE PAID FOR PARTICIPATING?
You will be paid for being in this research study. You will need to provide your social security number
(SSN) in order for us to pay you. You may choose to participate without being paid if you do not wish to
provide your social security number (SSN) for this purpose. You may also need to provide your address
if a check will be mailed to you. If your social security number is obtained for payment purposes only, it
will not be retained for research purposes.
You will be compensated a maximum of $300 for study involvement, depending on when you enter the
study in relation to your surgery. You will receive $50 for each preoperative (before surgery) recording
(up to $100 total for two days) for helping us record data while you sleep at home and for bringing the
device back to us. You will receive $25 for each postoperative study day, including the day of surgery and
up to seven days after surgery (maximum $200 for eight days). Cab fare will be arranged and paid for
ahead of any study-related outpatient visits by study staff to cover the cost of transportation for study
procedures. If otherwise requested by the patient, parking vouchers will also be assigned to participants
to cover the cost of parking for the duration of any required study-related visits.
WHO IS FUNDING THIS STUDY?
The National Institutes of Health (NIH) is funding this research study. This means that Washington
University is receiving payments from NIH to support the activities that are required to conduct the
study. No one on the research team will receive a direct payment or increase in salary from NIH for
conducting this study.
WHAT IF I AM INJURED AS A RESULT OF THIS STUDY?
Washington University investigators and staff will try to reduce, control, and treat any complications
from this research. If you feel you are injured because of the study, please contact the investigator (314)362-7823) and/or the Washington University Human Research Protection Office at 1-(800)-438-0445.
Decisions about payment for medical treatment for injuries relating to your participation in research will
be made by Washington University. If you need to seek medical care for a research-related injury, please
notify the investigator as soon as possible.
HOW WILL YOU KEEP MY INFORMATION CONFIDENTIAL?
We will keep your participation in this research study confidential to the extent permitted by law.
However, it is possible that other people such as those indicated below may become aware of your
participation in this study and may inspect and copy records pertaining to this research. Some of these
records could contain information that personally identifies you.
• Government representatives, (including the Office for Human Research Protections) to complete
federal or state responsibilities
• The U.S. Food and Drug Administration
• The National Institutes of Health
• Hospital or University representatives, to complete Hospital or University responsibilities
• Information about your participation in this study may be documented in your health care records
and be available to your health care providers who are not part of the research team.
• The last four digits of your social security number may be used in hospital or University systems
to track billing information for research procedures
• Washington University’s Institutional Review Board (a committee that oversees the conduct of
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research involving human participants) and the Human Research Protection Office. The
Institutional Review Board has reviewed and approved this study.
To help protect your confidentiality, we will have all paper documents locked in a filing cabinet in a
locked office of a member of the study team. We will keep all electronic documents on secured servers
that are password protected and have various state of the art firewall protections with frequent upgrades
of these protections. Access to these electronic research files will be restricted to members of the
research team and will be controlled by the principal investigator. If we write a report or article about
this study or share the study data set with others, we will do so in such a way that you cannot be directly
identified.
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required by U.S.
Law. This Web site will not include information that can identify you. At most, the Web site will
include a summary of the results. You can search this Web site at any time.
To further protect your privacy, this research is covered by a Certificate of Confidentiality from the
federal government. This means that the researchers can refuse to disclose information that may identify
you in any legal or court proceeding or to anyone who is not connected with the research except if:
• there is a law that requires disclosure, such as to report child abuse and neglect, or harm to self or
others;
• you give permission to disclose your information, including as described in this consent form; or
• it is used for other scientific research allowed by federal law.
You have the right to share your information or involvement in this study with anyone at any time. You
may also give the research team permission to disclose your information to a third party or any other
person not connected with the research.
If information about you or your involvement in this research is placed in your medical record the
information may no longer be protected under the Certificate. However, information in your medical
records is protected in other ways.
Are there additional protections for my health information?
Protected Health Information (PHI) is health information that identifies you. PHI is protected by federal
law under HIPAA (the Health Insurance Portability and Accountability Act). To take part in this
research, you must give the research team permission to use and disclose (share) your PHI for the study
as explained in this consent form. The research team will follow state and federal laws and may share
your health information with the agencies and people listed under the previous section titled, “How will
you keep my information confidential?”
Once your health information is shared with someone outside of the research team, it may no longer be
protected by HIPAA.
The research team will only use and share your information as talked about in this form or as permitted or
required by law. When possible, the research team will make sure information cannot be linked to you
(de-identified). Once information is de-identified, it may be used and shared for other purposes not
discussed in this consent form. If you have questions or concerns about your privacy and the use of your
PHI, please contact the University’s Privacy Officer at 866-747-4975.
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Your employer will have access to any email communications sent or received on any
electronic devices used for work or through a work server.

Do you agree to allow us to send your health information via email?
_____ Yes

_____ No

Initials

Initials

IS BEING IN THIS STUDY VOLUNTARY?
Taking part in this research study is completely voluntary. You may choose not to take part at all. If
you decide to be in this study, you may stop participating at any time. Any data that was collected as
part of your participation in the study will remain as part of the study records and cannot be removed.
If you decide not to be in this study, or if you stop participating at any time, you won’t be penalized or
lose any benefits for which you otherwise qualify.
What if I decide to withdraw from the study?
You may withdraw by telling the study team you are no longer interested in participating in the study or
you may send in a withdrawal letter. A sample withdrawal letter can be found at
https://hrpo.wustl.edu/participants/withdrawing-from-a-study/ under Withdrawing from a Research
Study.
Will I receive new information about the study while participating?
If we obtain any new information during this study that might affect your willingness to continue
participating in the study, we’ll promptly provide you with that information.
Can someone else end my participation in this study?
Under certain circumstances, the Principal Investigator (PI) might decide to end your participation in
this research study earlier than planned. This might happen for no reason or because you are found to be
ineligible for the study, or because your involvement causes significant distress/discomfort.
WHAT IF I HAVE QUESTIONS?
We encourage you to ask questions. If you have any questions about the research study itself, please
contact: We encourage you to ask questions. If you have any questions about the research study itself,
please contact:
Principal Investigator: Ben Palanca, M.D., Ph.D., M.Sc.
Mailing Address: Washington University School of Medicine / Department of Anesthesiology / Campus
Box 8054 / 660 South Euclid Avenue / St. Louis, MO / 63110
Telephone: 314-273-9076.
If you have questions, concerns, or complaints about your rights as a research participant, please contact
the Human Research Protection Office at 660 South Euclid Avenue, Campus Box 8089, St. Louis, MO
63110, 1-(800)-438-0445, or email hrpo@wustl.edu. General information about being a research
participant can be found on the Human Research Protection Office web site, http://hrpo.wustl.edu. To
offer input about your experiences as a research participant or to speak to someone other than the
research staff, call the Human Research Protection Office at the number above.
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This consent form is not a contract. It is a written explanation of what will happen during the study if
you decide to participate. You are not waiving any legal rights by agreeing to participate in this study.
As a participant you have rights and responsibilities as described in this document and including:
• To be given enough time before signing below to weigh the risks and potential benefits and
decide if you want to participate without any pressure from the research team or others.
• To understand all of the information included in the document, have your questions answered,
and receive an explanation of anything you do not understand.
• To follow the procedures described in this document and the instructions of the research team to
the best of your ability unless you choose to stop your participation in the research study.
• To give the research team accurate and complete information.
• To tell the research team promptly about any problems you have related to your participation, or
if you are unable to continue and wish to stop participating in the research study.
Your signature indicates that this research study has been explained to you, that your questions have
been answered, and that you agree to take part in this study. You will receive a signed and dated copy
of this form.
Do not sign this form if today’s date is after EXPIRATION DATE: 02/05/21.
__________________________________________
(Signature of Participant)

_______________________________
(Date)

____________________________________________
(Participant's name – printed)

Statement of Person Who Obtained Consent
The information in this document has been discussed with the participant or, where appropriate, with the
participant’s legally authorized representative. The participant has indicated that he or she understands
the risks, benefits, and procedures involved with participation in this research study.

__________________________________________
(Signature of Person who Obtained Consent)

_______________________________
(Date)

___________________________________________
(Name of Person who Obtained Consent - printed)
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